Home・Aandelen Lijst・TransMedics Group Inc

TransMedics Group Inc

Gesloten

SectorGezondheidszorg

80.5 -1.38

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

78.31

Max

81.92

Belangrijke statistieken
By Trading Economics
Inkomsten	-98M 7.3M
Verkoop	13M 174M
K/W Sectorgemiddelde	16.998 64.641
EPS	0.3
Winstmarge	4.206
Werknemers	898
EBITDA	-4.9M 28M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+41.02% upside

Dividenden
By Acuity
Volgende Winsten	4 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-786M 2.6B
Vorige openingsprijs	81.88
Vorige sluitingsprijs	80.5

Nieuwssentiment

By Acuity

65%

35%

289 / 340 Rangschikking in Healthcare

TransMedics Group Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 aug 2026, 19:51 UTC

Social Media

News

TransMedics Group Inc. shares are rising, despite an analyst downgrade to a $106 price target from $142, amid positive social media discussions.

30 jul 2026, 19:03 UTC

Transmedics Group Inc shares are lower during Thursday's session, with no specific news identified. Broader market uncertainty may be influencing the decline.

29 jul 2026, 23:36 UTC

Transmedics Group Inc. shares are lower in after-market trading, reflecting broader market volatility amid rising interest rates and geopolitical tensions.

28 jul 2026, 19:46 UTC

Transmedics Group Inc shares are higher today, advancing since Monday. The stock peaked earlier but pulled back from a session high.

27 jul 2026, 15:16 UTC

Social Media

News

Transmedics Group Inc is higher today amid social media discussions on its undervaluation and expectations for significant profit by 2028.

24 jul 2026, 20:02 UTC

Social Media

Transmedics Group Inc gains amid positive feedback from Jefferies on its technology and growth prospects, aligning with strength in the Health Care Equipment sector.

22 jul 2026, 19:46 UTC

Transmedics Group Inc shares are lower today, reflecting ongoing declines. The stock's volatility coincides with rising crude oil prices amid geopolitical tensions.

21 jul 2026, 14:36 UTC

Social Media

Transmedics Group's shares are higher today following the first lung transplant using its OCS warm-perfusion device, enhancing organ preservation and clinical outcomes.

20 jul 2026, 12:26 UTC

Social Media

TransMedics Group Inc shares are higher in pre-market trading amid strong operational growth, with flights exceeding 36 per day and projected revenue of $3 billion by 2032.

Peer Vergelijking

Prijswijziging

TransMedics Group Inc Prognose

Koersdoel

By TipRanks

41.02% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 115 USD 41.02%

Hoogste 175 USD

Laagste 80 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor TransMedics Group Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan TransMedics Group Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

289 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.